A generic version of a key cancer drug is now available in South Africa, but at a significantly higher cost than it is available internationally.
After a seven-year battle, India’s government has successfully defended its right to reject drug patents if a medicine doesn’t deserve one.
India’s Supreme Court has rejected a patent bid by Novartis in a ruling that will protect access to generics and save lives in developing countries.
Judgment is set to be delivered this week in the Novartis drug patent case in India.
SA healthcare has withstood court assaults by Big Pharma, but it will be dealt a tragic blow if a faraway battle over drug patents goes the wrong way.
Virus samples will be shared globally in exchange for vaccines produced from them under a landmark deal to improve preparedness for a flu pandemic.
Drugmakers’ traditional model is under threat from looming loss of exclusivity on some of the industry’s biggest sellers.
No image available
/ 22 September 2008
The WHO on Monday warned customers not to buy drugs made by Novartis’s Sandoz generics unit in SA after an inspection revealed more than 40 faults.
The World Health Organisation’s 193 member states on Saturday overcame their deep divisions over intellectual property rules and endorsed a strategy to help improve developing-country access to drugs and medical tests.